# Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial

> **NCT02678182** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 494 (actual)

## Conditions studied

- Adenocarcinoma of the Oesophagus
- Adenocarcinoma of the Gastro-oesophageal Junction
- Adenocarcinoma of the Stomach

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** MEDI4736 (Durvalumab)
- **DRUG:** Trastuzumab
- **DRUG:** Rucaparib
- **DRUG:** Ramucirumab

## Key facts

- **NCT ID:** NCT02678182
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-02
- **Primary completion:** 2025-04-17
- **Final completion:** 2027-06
- **Target enrollment:** 494 (ACTUAL)
- **Last updated:** 2025-06-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02678182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02678182, "Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02678182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*